NCT03286738Unknown不适用
Pattern of Use of Bevacizumab or Cetuximab in Patients With Metastatic Colorectal Cancer When Added to FOLFIRI Regimen as First-line Treatment; Multicenter, Registry Study
Joong Bae Ahn1 个研究点 分布在 1 个国家目标入组 1,800 人开始时间: 2015年11月最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1,800
- 试验地点
- 1
- 主要终点
- percentage of use FOLFIRI regimen and target agents
研究概览
简要总结
- Registry
- Multicenter, prospective observational study
- Observe adverse events and efficacy in recruited patients for 3 years under real world settings.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive Bevacizumab or Cetuximab in combination with FOLFIRI regimen as first-line treatment
- •Patients who will receive irinotecan, a component of FOLFIRI regimen, using Camtop Injection®
排除标准
- •Patients with conditions in which any study drug is contraindicated per the respective approved label.
结局指标
主要结局
percentage of use FOLFIRI regimen and target agents
时间窗: through study completion, 3 years
次要结局
未报告次要终点
研究者
Joong Bae Ahn
Professor
Yonsei University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck CancerHead and Neck CancerSquamous Cell CarcinomaNCT00409565National Cancer Institute (NCI)48
已完成
2 期
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell CarcinomaHead and Neck CancerNCT00968435Memorial Sloan Kettering Cancer Center30
已完成
不适用
Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT03170284Hoffmann-La Roche150
已完成
3 期
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric CancerAdenocarcinomaNCT00548548Genentech, Inc.774
已完成
不适用
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial ChemoembolizationUnresectable Hepatocellular CarcinomaNCT06503250Hoffmann-La Roche113